-
Rx Rundown: Sanofi, Bristol Myers Squibb, Omega Therapeutics and more
07 Feb 2025 13:05 GMT
… Parkinson’s disease treatment from Supernus Pharmaceuticals.
Cour Pharmaceuticals secured FDA … is eyeing a $135 million initial public offering.
Radiopharmaceuticals biotech AdvanCell raised a …
-
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
24 Apr 2022 22:08 GMT
… on Thursday, April 28.
Supernus Pharmaceuticals, Inc.'s … (before the market open)
IPOs
IPO Pricing
San Diego, California-based … 6 million shares in an initial public offering. This Cayman Islands exempted … million shares in an IPO, with the estimated price …
-
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
04 Nov 2021 12:37 GMT
… Drug Approval, Kidney Conference, More IPOs In The Pipeline
Chimerix Sinks … optimal dose of EZM0414.
Earnings
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)… )
IPOs
Hamburg, Germany-based Evotec SE (NASDAQ: EVO) priced its downsized initial public offering …
-
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct 2021 19:30 GMT
… NASDAQ: OCDX) (after the close)
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) … before the market open)
IPO Calendar
IPO Pricing
Hamburg, Germany-based … a 22-million ADS initial public offering at a price of … "NVCT."
IPO Quiet Period Expiry
Theseus …
-
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
16 Apr 2021 13:25 GMT
… Fisher Scientific Inc. (NYSE: TMO))
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) … trading.
On The Radar
IPOs
Biomea Fusion, Inc., a … cancers, priced its upsized initial public offering of 9 million shares at … clinical research, priced its IPO of 6.58 million …
-
The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
03 Apr 2021 13:16 GMT
… $175.5 million in an initial public offering.
Here are the key catalytic … early April its verdict on Supernus Pharmaceuticals, Inc.'s (NASDAQ … in HER2-positive solid tumors
IPOs
IPO Quiet Period Expiry
Prometheus Biosciences …
-
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO
30 Jan 2021 00:26 GMT
… )
Summit Therapeutics Inc (NASDAQ: SMMT)
Supernus Pharmaceuticals Inc (NASDAQ: SUPN)
Tenax … . (NYSE: RMD) (after the close)
IPOs
Raritan, New Jersey-based Ortho … Diagnostics Holdings plc priced its initial public offering of 76 million ordinary shares …
-
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
23 Dec 2020 14:14 GMT
… Treatment Aces Late-Stage Trial
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced … In Abbreviated Week Features 1 IPO, 1 FDA Decision
Pfizer-BioNTech … The Radar
IPOs
Atlanta-based Inhibikase Therapeutics Inc. priced its initial public offering of …
-
Former Biscayne Neurotherapeutics CEO aims to raise $75M through SPAC IPO
08 Dec 2020 19:55 GMT
… raise $75 million in an initial public offering to acquire businesses in the … , when it was sold to Supernus Pharmaceuticals (Nasdaq: SUPN) for $185 … traditional IPO.
More than 200 SPACs raised $73.4 billion through IPOs …
-
The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
08 Nov 2020 19:30 GMT
… is set to rule on Supernus Pharmaceuticals Inc.'s … ) (before the market open)
IPOs
Atlanta-based Inhibikase Therapeutics Inc … common stock in an initial public offering, or IPO, to be priced between … the ticker symbol INAB.
IPO Analysts' Quiet Period …